AstraZeneca rolls out Movantik; Novartis nabs FDA blessing for Jadenu; Indian drugmakers start hiring pharmacy grads as sales reps;

> AstraZeneca ($AZN) said the constipation-fighting drug Movantik has been launched in the U.S.; the company announced a marketing partnership with Daiichi Sankyo on the drug earlier this month. Release

> Novartis ($NVS) won FDA approval for Jadenu, a new oral formulation of its iron-chelation med Exjade. Release

> Novo Nordisk ($NVO) is preparing to roll out its hemophilia med Novoeight, approved in 2013 but unable to make its debut till mid-April because of patent issues. Release

> Indian drugmakers are recruiting pharmacy school grads to promote new specialty drugs, to reduce the need for training and better explain complex medications to doctors. Report

> A new study in JAMA Psychiatry showed that a once-quarterly version of Johnson & Johnson's ($JNJ) Invega drug significantly delayed relapses in patients with schizophrenia. Release

> Johnson & Johnson's ($JNJ) prostate cancer med Zytiga won FDA approval for new label information highlighting data on the pill's overall survival benefits in men not yet treated with chemo. Release

And Finally... A contrarian analyst questions big sales projections on cancer immunotherapies. Report

Suggested Articles

Horizon Therapeutics is preparing for the potential launch of inflammatory eye drug teprotumumab with team building.

Sanofi’s chief digital officer isn’t surprised to see CDOs popping up across Big Pharma. But they have to earn their keep, he says.

In a head-to-head against Bayer's Nexavar, Opdivo failed to significantly extend patients' lives in newly diagnosed liver cancer patients.